Vitalea Science Partners with SGS Life Science Services to Provide Microdosing Studies
News Nov 02, 2007
SGS announces that its Life Science Services division has selected Vitalea Science as a partner for providing Microdosing studies based on the Accelerator Mass Spectrometry (AMS) technology. This partnership further strengthens the complementary services offered by both SGS and Vitalea in executing early clinical trials based on the exploratory-IND concept.
Within the past three years, early phase clinical trials (Phase I-IIa) have evolved in process and purpose. New technology applications and shifts in the traditional drug development paradigm allow more information about drug candidates to be captured earlier in the process.
By harnessing the power of the AMS atom counter, one is able to collect ADME, bioavailability, and pharmacokinetic evaluations at the very earliest stages of clinical drug development: Phase 0 microdosing and Phase I microtracing. Streamlining early clinical development with microdosing and microtracers enables better development decisions, increasing potential success while reducing costs of failure for new drugs, formulations and delivery strategies.
In partnering with Vitalea Science, SGS is able to combine its own state of the art Phase I and bioanalytical facilities with Vitalea's AMS technology to provide clients with the necessary tools to execute these microdosing and microtracing studies. With new regulations in place as of June 2007, these exploratory IND studies can now be executed in SGS' Belgian facility.
High-Resolution Mass Spectrometry Reveals Pathways in Photosystem II Water SystemNews
Researchers have capitalised on the incredible accuracy, speed and sensitivity of new mass spectrometry instruments to provide the first comprehensive study of how an ancient photosynthetic organism uses and regulates water to create energy.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE